Performance of Xpert MTB/RIF Ultra: a matter of dead or alive

Lancet Infect Dis. 2018 Jan;18(1):8-10. doi: 10.1016/S1473-3099(17)30695-3. Epub 2017 Dec 5.

Authors

Sandra M Arend¹, Dick van Soolingen²

Affiliations

¹ Department of Infectious Diseases, Leiden University Medical Center, room C5P-40, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Electronic address: s.m.arend@lumc.nl.
² Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, Netherlands.

PMID: 29198910
DOI: 10.1016/S1473-3099(17)30695-3

No abstract available

Publication types

Comment

MeSH terms

Humans
Mycobacterium tuberculosis*
Prospective Studies
Rifampin
Tuberculosis, Multidrug-Resistant*
Tuberculosis, Pulmonary*

Substances

Rifampin